Tuesday’s packed schedule will let attendees hear from Anders Tveteraas, international head of patient solutions and services at Novartis and Julie Anderson, principal, behavioural health s
From Akili’s transition to over-the-counter to the downfall of Pear Therapeutics, it’s been an exciting time lately in the world of digital therapeutics.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
